{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:14:08Z","timestamp":1780348448872,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015283","name":"Bloomberg Philanthropies","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100015283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01126-3","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:09:40Z","timestamp":1732075780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experiences of the changing illicit drug supply among racial and ethnic minoritized people in three US states: a qualitative study"],"prefix":"10.1186","volume":"21","author":[{"given":"Brendan","family":"Saloner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia K.","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly C.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hridika","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hulsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Kerins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionna","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daliah","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachini","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"1126_CR1","doi-asserted-by":"publisher","first-page":"108416","DOI":"10.1016\/j.drugalcdep.2020.108416","volume":"218","author":"JN Park","year":"2021","unstructured":"Park JN, Rashidi E, Foti K, Zoorob M, Sherman S, Alexander GC. Fentanyl and fentanyl analogs in the illicit stimulant supply: results from U.S. drug seizure data, 2011\u20132016. Drug Alcohol Depend. 2021;218:108416. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108416.","journal-title":"Drug Alcohol Depend"},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"100197","DOI":"10.1016\/j.dadr.2023.100197","volume":"9","author":"M Cano","year":"2023","unstructured":"Cano M, Timmons P, Hooten M, Sweeney K. Drug supply measures and drug overdose mortality in the era of fentanyl and stimulants. Drug Alcohol Depend Rep. 2023;9:100197. https:\/\/doi.org\/10.1016\/j.dadr.2023.100197.","journal-title":"Drug Alcohol Depend Rep"},{"key":"1126_CR3","unstructured":"National Institute on Drug Abuse. Drug Overdose Death Rates. 2024. Accessed July 3, 2024. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates#:~:text=Figure%202.,overdose%20deaths%20reported%20in%202022"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"102833","DOI":"10.1016\/j.drugpo.2020.102833","volume":"93","author":"B Pardo","year":"2021","unstructured":"Pardo B. Supplying synthetic opioids during a pandemic: an early look at North America. Int J Drug Policy. 2021;93:102833. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102833.","journal-title":"Int J Drug Policy"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"103403","DOI":"10.1016\/j.drugpo.2021.103403","volume":"95","author":"R Foglia","year":"2021","unstructured":"Foglia R, Cooperman N, Mattern D, Borys S, Kline A. Predictors of intentional fentanyl use: market availability vs consumer demand. Int J Drug Policy. 2021;95:103403. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103403.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1126_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11524-024-00852-0","volume":"101","author":"AR Bazazi","year":"2024","unstructured":"Bazazi AR, Low P, Gomez BO, et al. Overdose from Unintentional Fentanyl Use when intending to use a non-opioid substance: an analysis of medically attended opioid overdose events. J Urban Health. 2024;101(2):245\u201351. https:\/\/doi.org\/10.1007\/s11524-024-00852-0.","journal-title":"J Urban Health"},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"103933","DOI":"10.1016\/j.drugpo.2022.103933","volume":"111","author":"C Russell","year":"2023","unstructured":"Russell C, Law J, Bonn M, Rehm J, Ali F. The increase in benzodiazepine-laced drugs and related risks in Canada: the urgent need for effective and sustainable solutions. Int J Drug Policy. 2023;111:103933. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103933.","journal-title":"Int J Drug Policy"},{"issue":"26","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","volume":"72","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl\u2013involved overdose deaths with detected xylazine \u2014 United States, January 2019\u2013June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7226a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1126_CR9","unstructured":"Drug Enforcement Administration. Xylazine. 2022. Accessed July 4, 2024. https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/Xylazine.pdf"},{"key":"1126_CR10","unstructured":"Drug Enforcement Administration. The Growing Threat of Xylazine and its Mixture with Illicit Drugs. 2022. Accessed July 4, 2024. https:\/\/www.dea.gov\/sites\/default\/files\/2022-12\/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf"},{"issue":"1","key":"1126_CR11","doi-asserted-by":"publisher","first-page":"e2350630","DOI":"10.1001\/jamanetworkopen.2023.50630","volume":"7","author":"M Cano","year":"2024","unstructured":"Cano M, Daniulaityte R, Marsiglia F. Xylazine in overdose deaths and forensic drug reports in US States, 2019\u20132022. JAMA Netw Open. 2024;7(1):e2350630. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50630.","journal-title":"JAMA Netw Open"},{"key":"1126_CR12","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109380.","journal-title":"Drug Alcohol Depend"},{"key":"1126_CR13","unstructured":"National Center for Health Statistics. Drug Overdose Deaths in the United States, 2002\u20132022. 2024. Accessed July 3, 2024. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db491.htm"},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"109859","DOI":"10.1016\/j.drugalcdep.2023.109859","volume":"246","author":"R Romero","year":"2023","unstructured":"Romero R, Friedman JR, Goodman-Meza D, Shover CL. US drug overdose mortality rose faster among hispanics than non-hispanics from 2010 to 2021. Drug Alcohol Depend. 2023;246:109859. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109859.","journal-title":"Drug Alcohol Depend"},{"issue":"29","key":"1126_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","volume":"71","author":"M Kariisa","year":"2022","unstructured":"Kariisa M, Davis NL, Kumar S, et al. signs Sdrug:overdoseedeathsDeathselectedlsociodemographicraphic and Social Determinants of Health Characteristics \u2014 25 States and the District of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2022;71(29):940\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7129e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"104368","DOI":"10.1016\/j.drugpo.2024.104368","volume":"126","author":"GC Dertadian","year":"2024","unstructured":"Dertadian GC. The coloniality of drug prohibition. Int J Drug Policy. 2024;126:104368. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104368.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1126_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12954-021-00564-7","volume":"18","author":"C Daniels","year":"2021","unstructured":"Daniels C, Aluso A, Burke-Shyne N, et al. Decolonizing drug policy. Harm Reduct J. 2021;18(1):120. https:\/\/doi.org\/10.1186\/s12954-021-00564-7.","journal-title":"Harm Reduct J"},{"key":"1126_CR18","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.478481","author":"RRR Banks","year":"2003","unstructured":"Banks RRR. Beyond profiling: race, policing, and the Drug War. SSRN J Published Online. 2003. https:\/\/doi.org\/10.2139\/ssrn.478481.","journal-title":"SSRN J Published Online"},{"key":"1126_CR19","doi-asserted-by":"publisher","unstructured":"Gibbons JB, Harris SJ, Solomon KT, Sugarman O, Hardy C, Saloner B. Increasing overdose deaths among Black Americans: a review of the literature. Lancet Psychiatry. Published online May 23, 2023:S2215-0366(23)00119-0. https:\/\/doi.org\/10.1016\/S2215-0366(23)00119-0","DOI":"10.1016\/S2215-0366(23)00119-0"},{"key":"1126_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drugpo.2018.08.004","volume":"60","author":"C McKnight","year":"2018","unstructured":"McKnight C, Des Jarlais DC. Being hooked up during a sharp increase in the availability of illicitly manufactured fentanyl: adaptations of drug using practices among people who use drugs (PWUD) in New York City. Int J Drug Policy. 2018;60:82\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.004.","journal-title":"Int J Drug Policy"},{"key":"1126_CR21","doi-asserted-by":"publisher","first-page":"882421","DOI":"10.3389\/fpubh.2022.882421","volume":"10","author":"SB Bass","year":"2022","unstructured":"Bass SB, Kelly PJA, Pandit-Kerr S, et al. It\u2019s my frenemy: a qualitative exploration of knowledge and perceptions of fentanyl use during the COVID-19 pandemic in people who use drugs at a syringe services program in Philadelphia, PA. Front Public Health. 2022;10:882421. https:\/\/doi.org\/10.3389\/fpubh.2022.882421.","journal-title":"Front Public Health"},{"key":"1126_CR22","doi-asserted-by":"publisher","first-page":"102900","DOI":"10.1016\/j.drugpo.2020.102900","volume":"84","author":"NP Weicker","year":"2020","unstructured":"Weicker NP, Owczarzak J, Urquhart G, et al. Agency in the fentanyl era: exploring the utility of fentanyl test strips in an opaque drug market. Int J Drug Policy. 2020;84:102900. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102900.","journal-title":"Int J Drug Policy"},{"key":"1126_CR23","doi-asserted-by":"publisher","first-page":"104391","DOI":"10.1016\/j.drugpo.2024.104391","volume":"127","author":"AB Collins","year":"2024","unstructured":"Collins AB, Macon EC, Levin S, Wunsch C, Wightman RS. It gets you high as a kite but not unsick: characterizations of and responses to a changing local drug supply by people who use drugs in Rhode Island. Int J Drug Policy. 2024;127:104391. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104391.","journal-title":"Int J Drug Policy"},{"key":"1126_CR24","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug Alcohol Depend Rep. 2022;4:100074. https:\/\/doi.org\/10.1016\/j.dadr.2022.100074.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/ADM.0000000000001264","volume":"18","author":"M Tan","year":"2024","unstructured":"Tan M, Nassau T, Kuncio D, et al. Xylazine use among people who inject drugs, Philadelphia 2022. J Addict Med. 2024;18(2):194\u2013200. https:\/\/doi.org\/10.1097\/ADM.0000000000001264.","journal-title":"J Addict Med"},{"key":"1126_CR26","unstructured":"Bandara S, Byrne L, Berman V et al. Harm Reduction and Treatment Among People at High Risk of Overdose. JAMA Network Open. In press."},{"issue":"1","key":"1126_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating Rigor using thematic analysis: a Hybrid Approach of Inductive and deductive coding and theme development. Int J Qualitative Methods. 2006;5(1):80\u201392. https:\/\/doi.org\/10.1177\/160940690600500107.","journal-title":"Int J Qualitative Methods"},{"key":"1126_CR28","unstructured":"Hassan S. In: Lewis DG, editor. Saving our own lives: a liberatory practice of harm reduction. Haymarket Books; 2022."},{"key":"1126_CR29","unstructured":"Szalavitz M. Undoing Drugs: How Harm Reduction Is Changing the Future of Drugs and Addiction. First paperback edition. Hachette Go; 2022."},{"issue":"4","key":"1126_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/10826084.2023.2177112","volume":"58","author":"P Fernandez","year":"2023","unstructured":"Fernandez P, Azucar D, Zambole K. A dose of truth: a qualitative Assessment of reactions to messages about fentanyl for people who use drugs. Subst Use Misuse. 2023;58(4):520\u20137. https:\/\/doi.org\/10.1080\/10826084.2023.2177112.","journal-title":"Subst Use Misuse"},{"key":"1126_CR31","doi-asserted-by":"publisher","unstructured":"Kutscher E, Barber Grossi M, LaPolla F, Lee JD. Fentanyl test strips for harm reduction: a scoping review. J Addict Med Published Online June. 2024;3. https:\/\/doi.org\/10.1097\/ADM.0000000000001321.","DOI":"10.1097\/ADM.0000000000001321"},{"key":"1126_CR32","unstructured":"Centers for Disease Control and Prevention. What You Should Know About Xylazine. May 16. 2024. Accessed October 31, 2024. https:\/\/www.cdc.gov\/overdose-prevention\/about\/what-you-should-know-about-xylazine.html"},{"key":"1126_CR33","doi-asserted-by":"publisher","first-page":"1359826","DOI":"10.3389\/fpsyt.2024.1359826","volume":"15","author":"AB Dankwah","year":"2024","unstructured":"Dankwah AB, Siegrist RB, Wilson IB, McKenzie M, Rich JD. Attitudes of black American christian church leaders toward Opioid Use Disorder, overdoses, and harm reduction: a qualitative study. Front Psychiatry. 2024;15:1359826. https:\/\/doi.org\/10.3389\/fpsyt.2024.1359826.","journal-title":"Front Psychiatry"},{"key":"1126_CR34","unstructured":"casey evan. Overdose deaths from Xylazine on the rise. 2024. Accessed July 5, 2024. https:\/\/www.wpr.org\/news\/overdose-deaths-from-xylazine-on-the-rise#:~:text=Overdose%20deaths%20involving%20a%20powerful,tranq%2C%E2%80%9D%20mixed%20with%20fentanyl"},{"key":"1126_CR35","unstructured":"White House Office of National Drug Control Policy. Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States. 2023. Accessed July 5, 2024. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/04\/12\/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states\/"},{"issue":"1","key":"1126_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12954-021-00528-x","volume":"18","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar ZR, Vincent L, et al. Treatment experiences for skin and soft tissue infections among participants of syringe service programs in North Carolina. Harm Reduct J. 2021;18(1):80. https:\/\/doi.org\/10.1186\/s12954-021-00528-x.","journal-title":"Harm Reduct J"},{"issue":"5","key":"1126_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1176\/appi.ajp.20230917","volume":"181","author":"JR Friedman","year":"2024","unstructured":"Friedman JR, Nguemeni Tiako MJ, Hansen H. Understanding and addressing widening racial inequalities in drug overdose. AJP. 2024;181(5):381\u201390. https:\/\/doi.org\/10.1176\/appi.ajp.20230917.","journal-title":"AJP"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01126-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:27:30Z","timestamp":1732091250000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01126-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01126-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"17 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was reviewed and approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors granted consent for publication. The interview guide for this study can be found in the appendix. Drs. Sherman and Saloner serve as expert witnesses on behalf of Baltimore City in its litigation against opioid manufacturers and distributors. The authors received support from the Bloomberg Philanthropies as part of The Bloomberg Overdose Prevention Initiative, a collaborative partnership aimed at combating the nation\u2019s opioid epidemic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs. Sherman and Saloner serve as expert witnesses on behalf of Baltimore City in its litigation against opioid manufacturers and distributors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}